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Hyperparathyroidism, platelet intracellular free calcium and hyperten-
sion in chronic renal failure. To investigate possible relationships
between hyperparathyroidism, alterations in intracellular free calcium
concentration ([Ca2j1) and hypertension in chronic renal failure, serum
concentrations of intact parathyroid hormone (PTH) were measured by
two-site immunometric assay, and platelet ([Ca2]1) was assessed using
the fluorescent indicator fura-2. Thirty-six patients with chronic renal
failure were studied, 10 with normal serum PTH concentrations (mean
8.0 0.6 pmollliter), 17 with elevated serum PTH (35.0 7.2
pmollliter) and 9 patients with elevated PTH (36.2 5.9pmol/liter) who
were receiving nifedipine. Platelet [Ca2] was increased in patients
with elevated PTH, compared with those in whom PTH was normal
(138 16 vs. 83 7 nmol/liter, P < 0.01). A linear relation was
observed between serum VFH and platelet [Ca21 in these patients (r =
0.818, P < 0.001). In contrast, platelet [Ca2] was not elevated (84 9
nmol/liter) in the patients with elevated PTH who were receiving
nifedipine. A linear relation was also present between both serum PTH
(r = 0.616, P < 0.001) and platelet [Ca2] (r = 0.576, P < 0.005) and
mean blood pressure. Nine patients with hyperparathyroidism were
restudied after treatment with the vitamin D analogue alfacalcidol. This
resulted in significant decreases in serum PTH (P < 0.01), platelet[Ca2] (P < 0,02), and mean blood pressure (P < 0.05). These studies
indicate that 1Ca2] may be increased early in renal failure, and that
this increase occurs in association with both hyperparathyroidism and
hypertension. Furthermore, treatment of hyperparathyroidism with
alfacalcidol may result in reductions in both [Ca2]1 and blood pressure.
The lack of elevation in [Ca2]1 in nifedipine-treated patients with
hyperparathyroidism suggests that, in uremia, increases in cytosolic
calcium induced by PTH or other factors may be mediated in part by
dihydropyridine-sensitive mechanisms.
Disordered calcium metabolism is very common in renal
disease, and abnormalities of calcium, phosphate, vitamin D
and parathyroid hormone may all occur. In the extreme case in
end-stage renal failure, this may lead to severe and widespread
extraosseous calcification [1]. However, secondary hyperpara-
thyroidism often develops early in the course of chronic renal
impairment [2, 3], and it has been suggested that parathyroid
hormone (PTH) may itself act as a uremic toxin [41 involved in
the neuropathy [5], cardiac dysfunction [6, 7], and other disor-
ders which may occur in renal failure. In support of this
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hypothesis, increases in total calcium content in the heart and
elsewhere have been documented in both clinical [8] and
experimental [9] renal failure, and these may be prevented by
parathyroidectomy [9].
Cytosolic free calcium, which plays a central role in intracel-
lular signaling, represents only a very small fraction of total
cellular calcium. Increases in cytosolic calcium have been
reported in experimental models of uremia [10] and in platelets
of patients with chronic renal failure [11], but the relationship of
this abnormality to the secondary hyperparathyroidism of ure-
mia remains unknown. It is also not known whether alterations
in cytosolic calcium in uremic patients are associated with
increases in blood pressure, as is the case in essential hyper-
tension [12—141.
In the present study we have therefore investigated the
possible relationship of intact serum PTH to platelet intracellu-
lar free calcium ([Ca2I1) and to blood pressure in patients with
chronic renal failure. In addition, the effects of the reversal of
hyperparathyroidism by alfacalcidol treatment on platelet intra-
cellular free calcium and on blood pressure have been studied.
Methods
Patients
Thirty-six Caucasian patients were included in the study, 23
males, 13 females, aged 18 to 77 years, mean 52 years. All had
chronic renal failure but none had end-stage disease requiring
maintenance dialysis. Details of patients are given in Table 1,
including the etiology of renal failure and drug treatment; this
was witheld on the day of study. The patients were divided into
three groups with: (a) serum PTH concentration less than 10
pmollliter (range 4.7 to 9.9 pM; N = 10), (b) serum PTH
concentration greater than 10 pmol/liter (range 11.0 to 106.8 pM;
N = 17), and (c) patients with serum PTH concentrations
greater than 10 pmollliter (range 10.8 to 57.5 pM) who were
receiving nifedipine therapy (N = 9). The groups were matched
for age and sex distribution, and degree of renal impairment. At
the beginning of the study no patient was receiving treatment
with alfacalcidol or other vitamin D analogue, and none had had
parathyroidectomy. Patients with evidence of autonomous hy-
perparathyroidism were excluded.
Blood samples were taken free-flowing, with the subject in
the seated position, between 9:00 and 10:30 a.m. For measure-
ment of serum PTH, 10 ml whole blood was allowed to stand for
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PTH PTH + nifedipine
Patient characteristic (N = 10) (N = 17) (N = 9)
Mean age (range) 55 (44—69) 52 (18—66) 53 (27—70)
Sex M/F 7/3 10/7 6/3
Diagnosis no. of patients
Glomerulonephritis 1 2 1
Pyelonephritis 2 5 1
Polycystic kidney disease 3 3 2
Diabetes mellitus 1 3 3
Hypertension 1 2 2
Other 2 2 —
Therapy no. of patients
Beta-blocker 4 8 4
Diuretic 6 10 7
ACE inhibitor 2 4 0
Vasodilator 1 6 5
Phosphate binder 6 10 5
Insulin 1 3 3
Other 6 7 1
Mean PTH pmol/liter 8.0 0.6 35.0 7.2 36.2 5.9
Mean creatinine .unol/liter 586 121 571 46 653 67
30 minutes and then centrifuged and serum stored at —70°C
until assay. For preparation of platelet-rich plasma and subse-
quent measurement of platelet intracellular free calcium, 5 to 10
ml blood was anticoagulated with 1/6 volume of acid-citrate
dextrose containing 65 m citric acid, 85 m sodium citrate and
110 mM dextrose. All measurements of serum PTH and of
platelet cytosolic calcium were carried out without knowledge
of the clinical status of the patient. Ten ml heparinized blood
was also taken for measurement of total and ionized plasma
calcium, plasma phosphate and alkaline phosphatase. Blood
pressure was recorded twice with a five-minute interval using a
'Copal' automated digital sphygmomanometer with the subject
seated, after 10 minutes rest. Diastolic pressure was recorded
as Korotkoff phase 5. Mean blood pressure was calculated as
(diastolic pressure + 1/3 pulse pressure). In nine patients
follow-up studies were carried out during treatment with alfa-
calcidol (0.25 to 1.0 g daily, mean 0.44 gIday) for a period of
2 to 11 months (mean 6.2 months).
Analytical procedures
Assay of serum PTH. Intact circulating PTH was measured
by a recently developed direct immunoassay described in detail
elsewhere [15]. The principle of the method involves formation
of an immune complex of labeled anti-amino terminal (1-34)
PTH antibody, intact human PTH and solid phase anti-mid
region (44-68) PTH antibody, with use of a chemiluminescent
aryl acridinium ester as tracer. One hundred microliter samples
of serum were used. Assay detection limit was 0.3 pmollliter of
1-84 PTH, and normal range 0.8 to 8.5 pmol/liter, determined in
82 subjects [15].
Measurement of platelet intracellular free calcium. Platelet
rich plasma (PRP) was prepared from 5 to 10 ml samples of
whole blood as previously described [16]. The PRP was then
incubated with 1 jsM fura-2 acetoxy methyl ester (fura-2/AM:
Molecular Probes Inc., Eugene, Oregon, USA) for 45 minutes
at 37°C. After the incubation the PRP was centrifuged at 350 x
g for 20 minutes and the platelet pellet resuspended in a
physiological saline (containing; (mM) 140 m sodium chloride,
5 m potassium chloride, 1 m magnesium sulphate, 10 mM
glucose, 10 mivi HEPES (pH 7.4), 100 LM aspirin, 20 sg/ml
apyrase and 0.05 U/ml hirudin), to which 1 m calcium chloride
(final) was subsequently added. The fluorescence from 1 ml
aliquots, excited at 340 nm, was monitored at 500 nm in a
Shimadzu spectrofluorimeter and was calibrated as follows; the
signal from each sample (F0) was recorded and the contribu-
tion to the signal from extracellular dye (Fik) determined by
adding 200 M manganese chloride. A total of 400 M DTPA
was then added to chelate the manganese; 50 sM digitonin was
added to lyse the cells giving Fdtg, followed by 2 m manganese
chloride to quench the signal giving FMfl. Fmax was taken as FdIS
— Fik, Fmin as [(Fmax — FMfl) 0.37 + FMfl] and Fr as F0 — Fik.
A value of 224 n was used as the Kd for fura-2 and Ca2 [17].
Using these values [Ca2]1 was calculated as described for
quin2 [18] with the equation [Ca2], = Kd [(Fr — Fmin)/(Fmax
— Fr)]. The emission spectra of the fura-2 loaded cells, exam-
ined for each patient's samples, showed no indication of Ca2-
insensitive forms of the dye as reported for polymorphonuclear
leukocytes [191. All determinations of platelet intracellular free
calcium were completed within four hours of obtaining blood
samples.
Plasma ionised calcium was determined with an Ion 83
lonmeter electrode (Radiometer). Plasma total calcium, phos-
phate, creatinine and alkaline phosphatase were measured with
an RA1000 automated analyzer.
Statistics
All results are expressed as mean SEM. Statistical compar-
ison was carried out using Student's t-test for paired or un-
paired normally distributed data, the Wilcoxon rank test for
non-parametric analysis, and regression analysis where indi-
cated.
Results
Serum parathyroid hormone concentrations
Serum PTH levels in the 36 patients ranged from 4.7 to 104.8
pmol/liter. Significant hyperparathyroidism was present in the
majority of patients, including those with relatively mild renal
failure (Fig. 1). Plasma total and free calcium, total phosphate
and alkaline phosphatase are shown in Table 2 for the three
groups of patients. Patients with hyperparathyroidism (PTH
greater than 10 pmollliter), whether treated with nifedipine or
not, tended to have lower total and free plasma calcium and
phosphate and higher alkaline phosphatase than patients with
essentially normal parathyroid function, although these differ-
ences did not achieve statistical significance.
Serum PTH and platelet intracellular free calcium
Platelet [Ca2i was significantly increased in the 17 patients
with increased PTH levels; 138 16 nmollliter (range 75 to 344
nmol/liter) compared to 83 7 nmol/liter (range 48 to 118
nmol/liter; P < 0.01) in patients with normal PTH. However,
platelet [Ca2I1 in the nine nifedipine-treated patients was not
elevated (84 9 nmol/liter) despite similar increases in PTH in
both these patients and the 17 hyperparathyroid patients (36.2
Study group
Elevated
Normal Elevated PTH +
PTH PTH nifedipine(N = 10) (N = 17) (N 9)
Serum PTH pmol/ 8.0 0.6 35.0 7.2 36.2 5.9
liter
Plasma total calcium 2.34 0.06 2.27 0.05 2.28 0.05
mmol/liter
Plasma free calcium 0.96 0.07 0.91 0.04 0.90 0.06
mmol/liter
Plasma phosphate 1.59 0.20 1.43 0.08 1.54 0.16
mmol/liter
Plasma alkaline 222 27 309 49 308 38
phosphatase
N 100—300 i.u./liter





Systolic 150 4 163 7 156 6
Diastolic 86 2 92 4 83 5
Mean 107 3 116 4 107 6
200 400 600 800
and 35.0 pmol/liter, respectively). For all patients, excluding
those receiving nifedipine therapy, there was a linear relation
between serum PTH concentrations and platelet [Ca2j1 (r
0.818; P < 0.001) as illustrated in Figure 2.
Serum PTH, platelet intracellular free calcium and blood
pressure
Systolic, diastolic and mean blood pressure were higher in
the 17 hyperparathyroid patients than in the 10 patients with
normal PTH (Table 2). When these 27 patients were subdivided
according to whether platelet intracellular free calcium was
greater or less than 100 nmol/liter, mean blood pressure was
higher in those with increased platelet [Ca2] (119 5 mm Hg,
N = 14) than in patients with low platelet [Ca2]1 (106 2 mm
Hg, N = 13; P < 0.05). Mean blood pressure was linearly
related to both serum PTH (r = 0.616, P < 0.001), and to
platelet [Ca2] (r = 0.576, P < 0.005), as shown in Figures 3
and 4.
To assess whether the low platelet [Ca2] in nifedipine-
treated patients was related to blood pressure reduction or
specifically to calcium entry blocker therapy, these patients
were compared to four hyperparathyroid patients receiving
hydralazine. Despite similar mean blood pressure (112 6 mm
Hg) and serum PTH (38.0 13.3 pmollliter) in the latter,
platelet [Ca2] was elevated at 140 30 nmollliter.
Effect of vitamin D therapy
Nine hyperparathyroid patients were re-studied during treat-
ment with alfacalcidol. Alfacalcidol therapy was associated
with a fall in serum PTH concentrations from 37 11 to 14
5 pmollliter (P < 0.01) and in platelet [Ca2]1 from 157 28 to
78 8 nmol/liter (P < 0.02). The changes in individual patients
are illustrated in Figure 5, which shows that in all cases, a fall
in PTH produced by vitamin D analogue therapy was associated
with a fall in platelet [Ca2]1, and conversely, an increase in
PTH with a rise in platelet [Ca2]1. Mean blood pressure also
fell significantly with alfacalcidol therapy (122 3 to 112 3
mm Hg; P < 0.05). The absolute change in mean blood pressure
during the treatment period was linearly related to both change
in serum PTH (r = 0.653; P < 0.05) and change in platelet
[Ca2]1 (r = 0.660; P < 0.05).
Discussion
The present study shows that intact serum parathyroid hor-
mone levels and cytosolic free calcium may both become
elevated early in the course of chronic renal failure, and both are
directly correlated. Although the causes of hyperparathyroidism
in chronic renal failure are complex [20], those contributing to this
abnormality in early renal failure include hypocalcemia secondary
to impaired renal hydroxylation of cholecalciferol [211 and renal
phosphate retention [22]. A direct association was observed
between serum PTH and platelet [Ca2]1 but it is not known
whether a causal relationship exists between these two vari-
ables, nor by what mechanism increased PTH might result in
elevated platelet [Ca2]1. In cultured renal proximal tubule
cells, PTH caused an immediate increase in [Ca2} through a
cyclic AMP-independent mechanism [23] involving stimulation
of production of inositol triphosphate and diacyl glycerol [24],
whereas in an osteoblast-like cell line, acute elevation of [Ca2j1
in response to PTH occurred through activation of both cyclic















Fig. 1. Serum PTH concentrations in relation to serum creatinine
concentrations in the 36 patients studied. Hatched area indicates
normal range for PTH, measured by two-site immunometric assay [lii.
20 40 60 80 100 120
Serum PTH, pmol/liter
Fig. 3. Relation between serum PTH concentration and mean blood
pressure in 27 patients (y = 0.35, x +103.9). r = 0.616; P < 0.001.
AMP-dependent and independent channels [25, 26]. It is un-
likely that increased cAMP mediates the elevation in platelet
[Ca2] which we observed; PTH has no apparent effect on
platelet cAMP in vitro [27], and in addition, cAMP in the
platelet is an inhibitory second messenger, associated with
reductions in [Ca211 [281.
In patients treated with alfacalcidol in the present study,
increases in both serum PTH and platelet [Ca2] were restored
towards normal. The reduction in serum PTH levels in response
to alfacalcidol is presumed due to both an increase in plasma
calcium, through increased gut absorption of calcium, and
direct suppression of parathyroid hormone secretion by vitamin
D [291. Although the possibility of a direct effect of alfacalcidol
therapy on platelet [Ca2]1 cannot be excluded, it seems more
likely that the fall in platelet [Ca2] was related in some way to
the concomitant reduction in serum PTH levels, since vitamin
Fig. 2. Relation between serum PTH
120 concentration and platelet intracellular free
calcium concentration in 27 patients (y = 1.8,
x +71.6). r = 0.818; P < 0.001.
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Fig. 4. Relation between platelet [Ca2 *]. and mean blood pressure in
27 patients (y = 0.15, x +95.3). r = 0.576; P < 0.005.
D may itself increase [Ca2]1 [301 and enhance cellular calcium
uptake [311. Comparison of the levels of serum PTH and [Ca2]
in patients receiving or not receiving nifedipine (Table 2)
suggests that chronic nifedipine therapy may, in contrast to
other vasodilators, also prevent elevation of [Ca2] in uremic
patients, even when hyperparathyroidism is present. The mech-
anism of this effect also remains unknown. Nifedipine has little
or no acute effect on resting or ADP-stimulated [Ca2], in
human platelets [32], although in osteoblastic cell lines, imme-
diate increases in cytosolic calcium induced by PTH were
inhibited by calcium channel blockers [26, 331. The implication
is that increases in cytosolic calcium in uremia, whether in-
duced by PTH or by other factors, may be mediated in part by
dihydropyridine-sensitive mechanisms.
Relationships between both serum PTH and platelet cytosolic
















































704 Raine et al: [Ca2'71 in CRF
calcium and blood pressure in patients with renal failure were
observed in the present study. In addition, alfacalcidol therapy
was associated with a reduction in blood pressure, which was
related to the decreases in both serum PTH and in platelet
[Ca2], in response to this therapy. Previous studies have
demonstrated a relationship in essential hypertension between
blood pressure and platelet [Ca2]1 [12, 13], though not lympho-
cyte [Ca2]1 [13, 34]. The mechanism of this relationship
remains unknown. However, recent studies in patients with
essential hypertension have shown relationships between intact
PTH, platelet [Ca2] and blood pressure similar to those
reported here [14]. Further studies in normotensive subjects
have confirmed a correlation between both intact PTH within
the normal range and platelet [Ca2] and blood pressure [35].
PTH was itself related to platelet [Ca2]1 in hypertensive
patients [14] but not normotensive subjects [35]. In these
studies, neither body mass index nor serum calcidiol nor
calcitriol were related to blood pressure. Thus, both the findings
of Brickman et al [14, 35] and those of the present study suggest
that one factor acting to elevate platelet [Ca2]1 in hypertension
and uremia may be serum PTH. However, it is likely that other
factors such as changes in cell calcium transport mechanisms or
membrane permeability in uremia may also contribute.
An alternative possibility is that increased platelet [Ca2]1
occurs secondary to the development of hypertension. If this
were the case, however, the fall in platelet [Ca2] with alfacal-
cidol therapy (Fig. 5) would imply that alfacalcidol exerted a
direct hypotensive effect. This appears unlikely, since serum
calcitriol is elevated in essential hypertension [14, 36], and
administration of calcitriol for three days enhanced vascular
smooth muscle contractility in spontaneously hypertensive rats
and in their normotensive controls [37].
The importance of both plasma volume status and plasma
renin activity in the pathogenesis of hypertension in renal
failure are well established [38]. The present study suggests that
hyperparathyroidism might also contribute to its development,
Fig. 5. Effects of 2 to 11 months' treatment
with alfacalcidol in 9 patients on serum PTH
concentration and platelet i cellular free
12 calcium concentration. Symbois are: (•)
values before commencement of alfacalcidol;
(0) corresponding values after treatment.
as experimental studies have previously suggested [391. The
relationships observed between PTH, intracellular calcium and
blood pressure were such that an increase in PTH from 10 to 50
pmol/liter was associated with a doubling of platelet [Ca2]1
from 100 to 200 nmollliter, and a 15 mm Hg increase in mean
blood pressure. In essential hypertension, the platelet [Ca2]1-
blood pressure relationship is steeper; an increase in [Ca2]1
from 100 to 200 nmollliter relates to a mean blood pressure
increase of 60 mm Hg [12, 13].
In summary, the present study shows that cytosolic free
calcium, assessed in platelets, may be increased relatively early
in the course of chronic renal failure, and this increase is
associated with elevation of serum PTH. The associations also
observed between both PTH and platelet cytosolic calcium and
blood pressure, together with the reductions in all these three
variables during the course of vitamin D therapy, suggest
mutual interrelationships which merit further investigation.
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